190 related articles for article (PubMed ID: 37285658)
21. Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product.
Nassar MN; Nesarikar VN; Lozano R; Parker WL; Huang Y; Palaniswamy V; Xu W; Khaselev N
Pharm Dev Technol; 2004; 9(2):189-95. PubMed ID: 15202578
[TBL] [Abstract][Full Text] [Related]
22. Factors Influencing Polysorbate's Sensitivity Against Enzymatic Hydrolysis and Oxidative Degradation.
Kranz W; Wuchner K; Corradini E; Berger M; Hawe A
J Pharm Sci; 2019 Jun; 108(6):2022-2032. PubMed ID: 30639738
[TBL] [Abstract][Full Text] [Related]
23. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
Doshi N; Martin J; Tomlinson A
Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
[TBL] [Abstract][Full Text] [Related]
24. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
[TBL] [Abstract][Full Text] [Related]
25. Effect of Fatty Acid Composition in Polysorbate 80 on the Stability of Therapeutic Protein Formulations.
Pegues MA; Szczepanek K; Sheikh F; Thacker SG; Aryal B; Ghorab MK; Wolfgang S; Donnelly RP; Verthelyi D; Rao VA
Pharm Res; 2021 Nov; 38(11):1961-1975. PubMed ID: 34845573
[TBL] [Abstract][Full Text] [Related]
26. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.
Kerwin BA
J Pharm Sci; 2008 Aug; 97(8):2924-35. PubMed ID: 17973307
[TBL] [Abstract][Full Text] [Related]
27. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
[TBL] [Abstract][Full Text] [Related]
28. On-line coupling of hydrophobic interaction column with reverse phase column -charged aerosol detector/mass spectrometer to characterize polysorbates in therapeutic protein formulations.
He Y; Brown P; Bailey Piatchek MR; Carroll JA; Jones MT
J Chromatogr A; 2019 Feb; 1586():72-81. PubMed ID: 30551943
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic understanding of metal-catalyzed oxidation of polysorbate 80 and monoclonal antibody in biotherapeutic formulations.
Bensaid F; Dagallier C; Authelin JR; Audat H; Filipe V; Narradon C; Guibal P; Clavier S; Wils P
Int J Pharm; 2022 Mar; 615():121496. PubMed ID: 35074436
[TBL] [Abstract][Full Text] [Related]
30. Stabilizing Polysorbate 20 and 80 Against Oxidative Degradation.
Schmidt A; Koulov A; Huwyler J; Mahler HC; Jahn M
J Pharm Sci; 2020 Jun; 109(6):1924-1932. PubMed ID: 32171713
[TBL] [Abstract][Full Text] [Related]
31. Analysis methods of polysorbate 20: A new method to assess the stability of polysorbate 20 and established methods that may overlook degraded polysorbate 20.
Khossravi M; Kao YH; Mrsny RJ; Sweeney TD
Pharm Res; 2002 May; 19(5):634-9. PubMed ID: 12069166
[TBL] [Abstract][Full Text] [Related]
32. Analytical strategies for controlling polysorbate-based nanomicelles in fruit juice.
Krtkova V; Schulzova V; Lacina O; Hrbek V; Tomaniova M; Hajslova J
Anal Bioanal Chem; 2014 Jun; 406(16):3909-18. PubMed ID: 24810233
[TBL] [Abstract][Full Text] [Related]
33. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability.
Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P
Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006
[TBL] [Abstract][Full Text] [Related]
34. Surface activity of a monoclonal antibody.
Mahler HC; Senner F; Maeder K; Mueller R
J Pharm Sci; 2009 Dec; 98(12):4525-33. PubMed ID: 19655376
[TBL] [Abstract][Full Text] [Related]
35. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
[TBL] [Abstract][Full Text] [Related]
36. The Impact of the Water Evaporation Rate and Saccharide Excipients on the Oxidative Degradation of Polysorbates During Oven Drying and Spray Drying.
Pinto JT; Rajkovaca M; Paudel A
J Pharm Sci; 2023 Jan; 112(1):36-39. PubMed ID: 36334810
[TBL] [Abstract][Full Text] [Related]
37. Micelle Driven Oxidation Mechansim and Novel Oxidation Markers for Different Grades of Polysorbate 20 and 80.
Kranz W; Wuchner K; Corradini E; Menzen T; Hawe A
J Pharm Sci; 2020 Oct; 109(10):3064-3077. PubMed ID: 32653599
[TBL] [Abstract][Full Text] [Related]
38. Degradation of polysorbate investigated by a high-performance liquid chromatography multi-detector system with charged aerosol and mass detection.
De Pra M; Ispan DA; Meding S; Müllner T; Lovejoy KS; Grosse S; Cook K; Carillo S; Steiner F; Bones J
J Chromatogr A; 2023 Nov; 1710():464405. PubMed ID: 37769426
[TBL] [Abstract][Full Text] [Related]
39. Characterization of Recombinantly-Expressed Hydrolytic Enzymes from Chinese Hamster Ovary Cells: Identification of Host Cell Proteins that Degrade Polysorbate.
Kovner D; Yuk IH; Shen A; Li H; Graf T; Gupta S; Liu W; Tomlinson A
J Pharm Sci; 2023 May; 112(5):1351-1363. PubMed ID: 36646283
[TBL] [Abstract][Full Text] [Related]
40. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients.
Santana H; González Y; Campana PT; Noda J; Amarantes O; Itri R; Beldarraín A; Páez R
Int J Pharm; 2013 Aug; 452(1-2):52-62. PubMed ID: 23624083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
